Arvaya posts ₹40.28 crore Q2 revenue and ₹1.37 crore PAT
Key highlights
- Arvaya reported ₹40.28 crore of revenue from operations in Q2 FY27, up 35% from ₹29.91 crore in Q1 FY27.
- Arvaya’s Q2 FY27 PAT was ₹1.37 crore, up 157% quarter on quarter, with a 3.4% PAT margin.
- Arvaya generated ₹8.16 crore of operating cash in H1 FY27, versus a ₹7.04 crore outflow in H1 FY26.
- Arvaya’s total assets were ₹173.15 crore at September 2026, compared with ₹140.62 crore at March 2026.
powered by IRIS

Arvaya Healthcare Limited reported ₹40.28 crore of revenue from operations and ₹1.37 crore of profit after tax in Q2 FY27, after SeCURE Hospitals was consolidated from 4 March 2026. Earnings before interest, tax, depreciation and amortisation, or EBITDA, reached ₹5.24 crore, while H1 FY27 operating cash flow was ₹8.16 crore.
Know Arvaya Healthcare inside out
Results, valuation, peers and who's buying, in one view.
What did Arvaya report in Q2 FY27?
Arvaya reported ₹40.28 crore in revenue from operations in Q2 FY27, ₹5.24 crore in EBITDA and ₹1.37 crore in profit after tax, or PAT. The respective margins were 13.0% at the EBITDA level and 3.4% at the PAT level. Earnings per share were ₹0.25 in the quarter, compared with a loss per share of ₹0.41 in Q2 FY26.
Arvaya’s H1 FY27 revenue from operations was ₹70.19 crore, with EBITDA of ₹9.21 crore and PAT of ₹1.90 crore. H1 EBITDA margin was 13.1% and PAT margin was 2.7%, while earnings per share were ₹0.33. Arvaya said year-on-year comparisons with Q2 FY26 and H1 FY26 are not meaningful because SeCURE Hospitals was consolidated from 4 March 2026 and the earlier periods reflected the pre-acquisition listed company only.
How did Arvaya’s profitability change from Q1 FY27?
Arvaya’s Q2 FY27 revenue increased 35% quarter on quarter from ₹29.91 crore in Q1 FY27 to ₹40.28 crore, while EBITDA rose 32% from ₹3.97 crore to ₹5.24 crore. EBITDA margin moved down by 25 basis points from 13.3% to 13.0%. A basis point is one-hundredth of a percentage point, making the reported margin movement equal to 0.25 percentage points.
PAT increased 157% quarter on quarter from ₹0.53 crore in Q1 FY27 to ₹1.37 crore in Q2 FY27, and the PAT margin rose 162 basis points from 1.8% to 3.4%. Profit before tax increased 137% from ₹0.56 crore to ₹1.32 crore. Other income rose from ₹0.19 crore to ₹0.53 crore, while depreciation and amortisation increased from ₹2.20 crore to ₹2.77 crore and finance cost increased from ₹1.39 crore to ₹1.67 crore.
Direct costs rose from ₹15.74 crore in Q1 FY27 to ₹20.48 crore in Q2 FY27, employee benefit expenses increased from ₹5.47 crore to ₹7.77 crore, and other expenses increased from ₹4.73 crore to ₹6.79 crore. Across H1 FY27, direct costs were ₹36.22 crore, employee benefits were ₹13.25 crore and other expenses were ₹11.51 crore. Arvaya also reported ₹4.97 crore of H1 depreciation and amortisation, ₹3.07 crore of finance cost and ₹1.90 crore of H1 PAT.
What does Arvaya’s September 2026 balance sheet show?
Arvaya’s total assets increased to ₹173.15 crore at September 2026 from ₹140.62 crore at March 2026, while total equity and liabilities increased by the same ₹32.53 crore. Total equity rose by ₹0.89 crore to ₹63.96 crore, including equity share capital unchanged at ₹48.02 crore, other equity of ₹12.47 crore and non-controlling interest of ₹3.46 crore.
Non-current liabilities increased to ₹54.41 crore from ₹44.89 crore, led by lease liabilities of ₹38.45 crore versus ₹35.44 crore and borrowings of ₹14.33 crore versus ₹8.05 crore. Current liabilities rose to ₹54.78 crore from ₹32.67 crore. Within current liabilities, borrowings rose to ₹17.01 crore from ₹2.52 crore and lease liabilities increased to ₹14.85 crore from ₹3.38 crore, while trade payables declined to ₹8.57 crore from ₹11.41 crore.
On the asset side, non-current assets rose to ₹121.48 crore from ₹102.52 crore, including right-of-use assets of ₹52.80 crore, compared with ₹39.89 crore at March 2026. Property, plant and equipment increased to ₹26.58 crore from ₹23.81 crore, and goodwill and intangibles, including assets under development, reached ₹28.59 crore from ₹28.34 crore. Current assets rose to ₹51.66 crore from ₹38.11 crore, with trade receivables increasing to ₹7.04 crore from ₹2.20 crore and cash and cash equivalents increasing to ₹2.79 crore from ₹2.35 crore.
Got a follow-up? Ask IRIS
What did Arvaya’s cash flow and operating plan indicate?
Arvaya generated ₹8.16 crore of net cash from operating activities in H1 FY27, compared with an outflow of ₹7.04 crore in H1 FY26. Profit before tax was ₹1.88 crore, and non-cash adjustments of ₹7.38 crore resulted in operating profit before working-capital changes of ₹9.26 crore. Working-capital changes used ₹1.10 crore, compared with a ₹6.42 crore use in H1 FY26.
Investing activities consumed ₹15.85 crore in H1 FY27, while financing activities generated ₹8.14 crore. The resulting net increase in cash was ₹0.45 crore, taking closing cash and cash equivalents to ₹2.79 crore from opening cash of ₹2.35 crore. The consolidated, unaudited cash-flow statement records no direct taxes paid for H1 FY27.
Management’s FY27 plan includes about 800 beds under management, the launch of the ArvayaSecure app, full SeCURE network rollout, and a clinic hub with pharmacy and laboratory services. The H1 FY27 operating base was 517 beds, with a SecurANT pilot at SeCURE and ₹70 crore of hospital revenue stated for the half year. Arvaya also plans to repurpose the 44-key Goa resort held by its 100% owned Arvaya Healthtech & Wellness Pvt Ltd subsidiary.
Conclusion
Arvaya’s first reported Q2 FY27 profile following SeCURE Hospitals consolidation combines ₹40.28 crore of quarterly revenue, ₹5.24 crore of EBITDA and ₹1.37 crore of PAT with ₹8.16 crore of H1 operating cash generation. Compared with Q1 FY27, revenue and PAT increased 35% and 157%, respectively, although EBITDA margin decreased 25 basis points to 13.0% as direct costs, employee costs and other expenses also increased.
The next disclosed markers are management’s FY27 target of about 800 beds under management and its technology, app and clinic-hub rollouts. Management’s longer-term plan calls for about 1,200 beds in FY28 and about 2,400 beds under operations and management by FY30, alongside a ₹600 crore revenue trajectory; Arvaya states that these forward-looking plans are subject to risks, uncertainties and assumptions.


